Merios
Inflammation

Inflammation Markers: The Silent Health Threat

Inflammation markers like hs-CRP, homocysteine, and ferritin reveal hidden low-grade inflammation. What an inflammation markers blood test really shows.

JUL 20, 20269 MIN READINFLAMMATIONMERIOS EDITORIAL
Contents
  1. Acute vs. Chronic Low-Grade Inflammation
  2. hs-CRP: The Marker That Anchors the Panel
  3. Homocysteine: The Amino Acid Marker Most Panels Skip
  4. Ferritin: An Inflammation Marker in Disguise
  5. Fibrinogen, White Blood Cells, and the Neutrophil-to-Lymphocyte Ratio
  6. What Chronic Inflammation Means for Long-Term Risk
  7. What to Do If Your Inflammation Markers Are High

Inflammation Markers: The Silent Health Threat

Most of the conditions that quietly shorten a modern lifespan — heart attacks, strokes, type 2 diabetes, and several cancers — share a common thread: chronic, low-grade inflammation. It rarely produces anything you can feel. There is no fever, no swelling, no obvious pain. Instead it simmers in the background for years, slowly damaging blood vessels, disrupting how your body handles glucose, and accelerating the aging of nearly every tissue. The only reliable way to see it is to measure it, and that is exactly what a panel of inflammation markers in your blood is designed to do.

An inflammation markers blood test is not a single number. It is a small cluster of related measurements — hs-CRP, homocysteine, ferritin, fibrinogen, white blood cell indices — that, read together, estimate how much inflammatory activity is running in the background. This article is the map for that cluster. Where a specific marker deserves its own deep dive, you will find a link to it.

Acute vs. Chronic Low-Grade Inflammation

Inflammation itself is not the enemy. It is one of the most important defenses your body has. When you cut your finger or catch a virus, the acute inflammatory response floods the area with immune cells, clears the threat, and then, crucially, resolves. Redness fades, swelling goes down, and the marker levels return to baseline within days. That is inflammation doing its job.

The problem is a different pattern: chronic, low-grade inflammation. Here the inflammatory signal never fully switches off. It stays low enough that you feel nothing, but high enough that, over years, it damages the lining of your arteries, promotes the plaques behind heart disease, and interferes with insulin signaling. Researchers sometimes call the age-related version of this "inflammaging."

This distinction matters for how you read your results. A markedly high marker during a week you had the flu tells you almost nothing about your long-term risk. A modestly elevated marker that stays elevated on a calm, healthy repeat test is the signal worth paying attention to. Timing and repetition, not a single dramatic value, are what make inflammation markers useful.

hs-CRP: The Marker That Anchors the Panel

If you measure only one inflammation marker, it should be high-sensitivity C-reactive protein (hs-CRP). CRP is a protein made by your liver in response to inflammatory signals, and the high-sensitivity assay is precise enough to detect the low levels that predict cardiovascular risk in otherwise healthy people. It is the best-studied inflammation marker in cardiology and the natural anchor of the panel. For the mechanics of what CRP is and how the liver produces it, our primer on what CRP actually measures covers the biology in full.

The American Heart Association and CDC use three consensus bands for cardiovascular risk:

  • Under 1.0 mg/L — low risk
  • 1.0 to 3.0 mg/L — average risk
  • Above 3.0 mg/L — high risk

A value in the top band does not diagnose disease, but it does warrant attention. If your result lands there, our breakdown of an hs-CRP reading of 3.0 mg/L and the deeper analysis of what CRP above 3 means for heart risk walk through what to do next and what your clinician may look for.

Two landmark trials explain why cardiologists take hs-CRP seriously. In the JUPITER trial (Ridker et al., New England Journal of Medicine, 2008), nearly 18,000 apparently healthy adults with normal LDL cholesterol but hs-CRP of 2.0 mg/L or higher were given a statin or placebo. The statin group had roughly 44 percent fewer major cardiovascular events, showing that elevated inflammation flagged real risk even when cholesterol looked fine.

JUPITER, though, could not fully separate the statin's cholesterol-lowering effect from its anti-inflammatory effect. That separation came with CANTOS (Ridker et al., New England Journal of Medicine, 2017). CANTOS gave canakinumab — an antibody that blocks the inflammatory signal interleukin-1 beta — to more than 10,000 heart attack survivors with elevated hs-CRP. The drug lowered inflammation without changing cholesterol at all, and it still reduced recurrent cardiovascular events. That result was the first strong evidence that inflammation is not just a bystander marker but part of the causal chain of heart disease. (Canakinumab is not used as a routine inflammation treatment; the trial's value is what it proved about the biology.)

Homocysteine: The Amino Acid Marker Most Panels Skip

Homocysteine is not a protein or a classic inflammatory molecule — it is an amino acid your body produces while processing methionine from dietary protein. It earns a place on an inflammation and cardiovascular panel because elevated levels are associated with damage to the vessel wall and with higher cardiovascular risk, and because it is rarely included on standard blood work unless you specifically ask.

What makes homocysteine appealing as a marker is that it is often responsive to simple nutrients. The B vitamins — folate, B12, and B6 — are cofactors your body uses to clear homocysteine, and deficiency in any of them can drive levels up. It is worth being precise here: while lowering homocysteine with B vitamins reliably brings the number down, large trials have not consistently shown that doing so reduces heart attacks, so it is best treated as a risk-associated signal to investigate rather than a target to chase in isolation. Our full guide to high homocysteine and heart risk explains the B-vitamin connection and how the number is interpreted.

Ferritin: An Inflammation Marker in Disguise

Ferritin is best known as a measure of iron stores, and it usually is one. But it is also an acute-phase reactant, meaning it rises as part of the inflammatory response itself. This creates one of the most common traps in reading blood work: a high ferritin does not automatically mean you have too much iron.

Inflammation, infection, liver stress, heavy alcohol use, and metabolic syndrome can all push ferritin up independently of your actual iron reserves. So a person with genuinely normal or even low usable iron can show a high ferritin simply because their body is inflamed. This is why ferritin should never be read alone. When ferritin is high, clinicians typically look at it alongside hs-CRP and iron-specific measures like transferrin saturation: if inflammation markers are also elevated, the high ferritin may be reflecting that inflammation rather than iron overload. Interpreted in context, ferritin becomes a genuinely useful part of the inflammation picture instead of a misleading one.

Fibrinogen, White Blood Cells, and the Neutrophil-to-Lymphocyte Ratio

Several markers round out the panel, each adding a slightly different angle.

Fibrinogen is a clotting protein and, like CRP and ferritin, an acute-phase reactant that rises with inflammation. Higher fibrinogen is associated with greater cardiovascular risk, partly because it both signals inflammation and contributes to the tendency of blood to clot.

White blood cell (WBC) count, a standard part of any complete blood count, is a coarse but real indicator. A WBC count sitting in the upper part of the normal range has been associated in population studies with higher cardiovascular risk, since white cells are central players in the inflammatory process, which is why the total white count is worth a second look even when it reads as technically normal.

The neutrophil-to-lymphocyte ratio (NLR) is derived by dividing the neutrophil count by the lymphocyte count, both already reported on a routine differential. It has drawn growing interest as an inexpensive marker of systemic inflammation, with higher ratios linked to worse outcomes across a range of conditions. It is still best viewed as a supporting signal alongside hs-CRP rather than a standalone verdict. GGT (gamma-glutamyl transferase), often thought of purely as a liver enzyme, also tracks with oxidative stress and metabolic inflammation, which is why an elevated GGT can be a clue worth noting even when the rest of the liver panel looks unremarkable.

What Chronic Inflammation Means for Long-Term Risk

The reason all of these markers belong together is that chronic low-grade inflammation is not confined to one organ. It is a whole-body process with a broad footprint.

In the cardiovascular system, inflammation drives the formation and instability of arterial plaques — the mechanism JUPITER and CANTOS illuminated. Metabolically, inflammatory signaling interferes with insulin, and elevated inflammation markers frequently travel alongside insulin resistance and the early stages of type 2 diabetes. Over a longer horizon, the same "inflammaging" process is associated with frailty, slower recovery, and the biological aging of tissues, and chronic inflammation appears in the background of some cancers and neurodegenerative conditions as well.

None of this means one elevated marker predicts a specific outcome. These are statistical associations across large populations, not a diagnosis for any individual. But the pattern is consistent enough that persistently high inflammation markers are best read as an early, actionable warning rather than background noise — a signal that the terrain is worth improving before problems become clinical.

What to Do If Your Inflammation Markers Are High

The encouraging part of the story is that low-grade inflammation is often responsive to ordinary, evidence-based changes. None of the following is a treatment for a disease, and a single high reading should always be repeated and discussed with a clinician before you draw conclusions. But when markers like hs-CRP are genuinely and repeatedly elevated, these levers are where the research points.

  1. Sleep. Short and poor-quality sleep is consistently associated with higher inflammatory markers. Protecting seven to nine hours of consolidated sleep is one of the most underrated inflammation interventions.
  2. Regular physical activity. Habitual moderate exercise is associated with lower CRP over time. The effect comes from consistency rather than occasional intense sessions.
  3. An anti-inflammatory diet. Mediterranean-style eating — rich in vegetables, legumes, whole grains, and omega-3 fats — is associated with lower inflammation. Because the omega-3 fatty acids in fish are a particular focus here, the omega-3 index blood test is a useful way to see whether your intake is actually reaching your tissues.
  4. Dental and gum health. Chronic gum inflammation (periodontitis) is associated with higher systemic inflammatory markers, so routine dental care is a genuine, if often overlooked, part of the picture.
  5. Reducing visceral fat. The fat stored around your abdominal organs is metabolically active and secretes inflammatory signals. Losing visceral fat, in particular, is associated with meaningful drops in inflammation markers.
  6. Not smoking. Smoking is a direct and powerful driver of systemic inflammation, and stopping is among the highest-impact changes available.

For a fuller, evidence-ranked walkthrough of these strategies and roughly how much each tends to move the number, our guide to how to lower CRP levels breaks them down in detail.

Read one at a time, inflammation markers are easy to dismiss — a slightly high value here, a borderline number there. Read together, and tracked over time, they tell a coherent story about a health threat that is otherwise invisible. Merios reads hs-CRP, homocysteine, ferritin, and the rest of your inflammatory markers as a single connected panel, so the pattern shows up long before it would ever announce itself.

Merios EditorialEditorially reviewed · Sources cited inlineResearch-backed health insights from the Merios team. Read our methodology
Share
Baseline · The Newsletter

One biomarker, explained properly, every week.

Plain-English deep-dives on what your labs actually mean — functional ranges, trends, and the studies behind them. Free, no spam.

Frequently asked questions

Newsletter

Like this? Get the next one in your inbox.

Merios is live on the US App Store — plus a weekly briefing with new biomarker deep-dives and plain-English study breakdowns.